Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DISULFIRAM vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive effects such as flushing, nausea, and hypotension.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Alcohol dependence (FDA-approved),Off-label: Cocaine dependence (limited evidence)
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
250 mg orally once daily, increased to 500 mg orally once daily if needed; maintenance dose typically 250 mg per day (range 125-500 mg).
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Approximately 7–10 hours for parent drug; however, the disulfiram-ethanol reaction can persist up to 14 days due to irreversible inhibition of aldehyde dehydrogenase (ALDH) and slow regeneration of the enzyme. The active metabolite, diethyldithiocarbamate, has a half-life of about 15 hours.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Disulfiram is rapidly metabolized in the liver to diethyldithiocarbamate, which is further metabolized; it is primarily excreted in urine and feces.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Primarily renal as metabolites; approximately 80% of a dose is excreted in urine as glucuronide conjugates and other metabolites, with less than 20% excreted in feces via bile. A small amount is eliminated unchanged in urine.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Approximately 96% bound primarily to albumin and also to lipoproteins.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Approximately 2–4 L/kg, indicating extensive tissue distribution and accumulation, particularly in adipose tissue due to lipophilicity.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Rapidly and almost completely absorbed after oral administration; absolute bioavailability is approximately 70–90% due to first-pass metabolism in the liver. No parenteral forms are approved; only oral route (tablets) is used clinically.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
No dose adjustment required for renal impairment; no specific GFR-based guidelines exist; use with caution in severe renal impairment.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment, but monitor liver function. Not recommended in active liver disease.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Not recommended for use in patients under 18 years due to lack of established safety and efficacy.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at lower dose (125 mg/day) due to age-related decreased function; monitor closely for adverse effects.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Disulfiram should never be administered to a patient who is in a state of alcohol intoxication or without the patient's full knowledge and consent. The patient must be fully informed of the disulfiram-alcohol reaction.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Hepatotoxicity including hepatitis and hepatic failure; peripheral neuropathy; optic neuritis; psychotic reactions; hypersensitivity; risk of severe disulfiram-alcohol reaction if alcohol is consumed.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Concurrent use of alcohol or alcohol-containing preparations; metronidazole; paraldehyde; severe myocardial disease; coronary occlusion; psychosis; severe hepatic impairment; hypersensitivity to disulfiram or other thiuram derivatives.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Avoid foods and products containing alcohol: sauces (e.g., wine sauces, beer batter), vinegar (especially red/white wine vinegar), marinades, ripe fruits (fermentation can produce trace alcohol), some desserts (e.g., tiramisu, fruitcakes), alcohol-infused chocolates, non-alcoholic beer/wine (may contain up to 0.5% alcohol). Also avoid mouthwashes, breath sprays, and hand sanitizers with ethanol. Some medications like paraldehyde, chloral hydrate, and metronidazole may cross-react. Even alcohol in cooking may not fully evaporate and can trigger a reaction.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxic effects at high doses. Avoid unless benefit outweighs risk. Second and third trimesters: No specific malformation patterns reported; however, theoretical risk of disulfiram-ethanol reaction causing fetal hypoxia due to maternal acetaldehyde accumulation. Use only if essential and with strict alcohol avoidance.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Excreted into breast milk in small amounts (M/P ratio not established). No adverse effects reported in nursing infants. However, theoretical risk of disulfiram-ethanol reaction if mother consumes alcohol. Recommend caution and discuss with healthcare provider; generally consider compatible with breastfeeding if mother abstains from alcohol.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No specific dose adjustment recommended in pregnancy. Pharmacokinetic studies in pregnancy not available. Use lowest effective dose (typically 250 mg/day) to minimize risks. Avoid higher loading doses. Discontinue if signs of hepatotoxicity occur.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to severe nausea, vomiting, hypotension, and flushing. Avoid use in patients with severe heart disease, psychosis, or cirrhosis. Monitor LFTs and CBC at baseline and periodically. Disulfiram may also inhibit CYP450 enzymes (CYP2E1, CYP1A2, CYP3A4), potentiating warfarin, phenytoin, and theophylline. Onset of aversion therapy requires 12-48 hours after the last alcohol dose; maintain alcohol-free period of 24 hours before starting. Duration of action persists up to 14 days after discontinuation. Inadvertent alcohol exposure in topical products (mouthwash, colognes) can trigger reactions.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Avoid all forms of alcohol, including beverages, mouthwash, cough syrup, cooking wine, vinegar, aftershave, and hand sanitizers.,Reaction to alcohol includes severe flushing, nausea, vomiting, chest pain, difficulty breathing, and blurred vision; seek emergency care if symptoms occur.,The disulfiram-alcohol reaction can be fatal even with small amounts of alcohol.,Inform all healthcare providers (including dentists) that you are taking disulfiram.,Reactions may occur up to 14 days after stopping the medication.,Do not take disulfiram if you have recently consumed alcohol; wait at least 12 hours after the last drink.,Carry a medical alert card or wear a bracelet stating you are on disulfiram.,Report any signs of liver toxicity: yellowing of eyes/skin, dark urine, severe fatigue.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"Rifapentine, a potent inducer of cytochrome P450 enzymes, significantly increases the metabolism of disulfiram by inducing hepatic CYP3A4 and other metabolic pathways. This induction reduces disulfiram plasma concentrations, potentially diminishing its therapeutic efficacy in maintaining alcohol aversion. The interaction may lead to an increased risk of alcohol consumption relapse and associated clinical consequences."
"Disulfiram inhibits aldehyde dehydrogenase, leading to acetaldehyde accumulation, but also inhibits CYP3A4 and other CYP enzymes. Palbociclib is primarily metabolized by CYP3A4 and is a substrate of this enzyme. Coadministration with disulfiram can significantly increase palbociclib serum concentrations, raising the risk of dose-dependent toxicities such as neutropenia, infections, and fatigue."
"Disulfiram irreversibly inhibits aldehyde dehydrogenase and also suppresses the activity of cytochrome P450 (CYP) 2D6 and other CYP enzymes, thereby reducing the hepatic metabolism of venlafaxine. This can lead to increased plasma concentrations of venlafaxine and its active metabolite O-desmethylvenlafaxine, elevating the risk of dose-dependent adverse effects such as hypertension, nausea, dizziness, and serotonin syndrome. Additionally, disulfiram's own metabolism may be affected, potentially increasing the severity of disulfiram-ethanol reactions."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DISULFIRAM vs ALFENTA, answered by our medical review team.
DISULFIRAM is a Aldehyde Dehydrogenase Inhibitor that works by Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive effects such as flushing, nausea, and hypotension.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DISULFIRAM and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DISULFIRAM is: 250 mg orally once daily, increased to 500 mg orally once daily if needed; maintenance dose typically 250 mg per day (range 125-500 mg).. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DISULFIRAM and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DISULFIRAM is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxic effects at high doses. Avoid unless benefit outweighs risk. Second and third trimesters: . ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.